Pascal Gasser
Research Subjects
Pascal Gasser has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Eggel
Department for BioMedical Research University of Bern Bern Switzerland
4 shared publications - Theodore S. Jardetzky
Department of Structural Biology Stanford University School of Medicine Stanford California USA
3 shared publications Daniel Brigger
Department of Rheumatology, Immunology and Allergology, Bern University Hospital, University of Bern, Bern, Switzerland
2 shared publications- Georgios Skiniotis
Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA
2 shared publications - Luke F. Pennington
Excellergy Inc. San Jose California USA
2 shared publications - Pascal Guntern
Universitat Bern Department for BioMedical Research
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Peanut‐Specific IgG4 mAbs Promote Regulatory Immune Responses Ex Vivo and Improve Oral Immunotherapy in Mice
Background: Peanut allergy remains a clinical challenge, with limited treatment options such as omalizumab (Xolair) and allergen immunotherapy (AIT). However, these are constrained by eligibility and safety concerns. AIT induces protective allergen‐neutralizing IgG4 in most, but not all patients. Allergen‐neutralizing IgG4 competes with allergen‐specific IgE, inhibits FcεRI‐mediated mast cell activation, and inhibits IgE‐facilitated antigen presentation via CD23. Recent findings suggest that combining omalizumab with AIT enhances safety and reduces side effects. We hypothesize that controlled allergen exposure combined with peanut‐specific IgG4 mAbs (MY‐4‐mAbs) prevents IgE binding to peanut allergens, reduces CD23‐mediated allergen presentation and Th2 responses, and skews immunity towards protective allergen‐specific IgG while limiting allergen‐specific IgE induction. Methods: PBMCs from peanut‐allergic donors were exposed to Ara h 2 with or without MY‐4‐mAbs. Th2 cytokines, Foxp3+ Tregs, and IgE‐facilitated allergen binding (FAB) to B cells were assessed. In vivo, peanut‐sensitized C3H/HeJ mice underwent oral‐AIT with peanut extract with or without MY‐4‐mAbs and were monitored for anaphylaxis during and after oral‐AIT. Additionally, peanut‐specific IgG and IgE levels were measured before and after oral‐AIT. Results: Ex vivo, MY‐4‐mAbs with Ara h 2 suppressed Th2 cytokines, enhanced IL‐10 secretion, and inhibited FAB. MY‐4‐mAbs redirected allergen binding to myeloid antigen‐presenting cells and promoted tolerance‐associated responses. In vivo, the combination maintained peanut‐specific IgG induced during oral‐AIT, prevented increases in IgE, and reduced mast cell activation. Conclusions: Allergen‐specific IgG4 mAbs with controlled allergen exposure may improve the safety and efficacy of peanut AIT while promoting tolerance‐associated immune responses, which might allow disease modification towards allergen tolerance.
- 22 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Open AccessPeanut‐Specific IgG4 mAbs Promote Regulatory Immune Responses Ex Vivo and Improve Oral Immunotherapy in Mice
Background: Peanut allergy remains a clinical challenge, with limited treatment options such as omalizumab (Xolair) and allergen immunotherapy (AIT). However, these are constrained by eligibility and safety concerns. AIT induces protective allergen‐neutralizing IgG4 in most, but not all patients. Allergen‐neutralizing IgG4 competes with allergen‐specific IgE, inhibits FcεRI‐mediated mast cell activation, and inhibits IgE‐facilitated antigen presentation via CD23. Recent findings suggest that combining omalizumab with AIT enhances safety and reduces side effects. We hypothesize that controlled allergen exposure combined with peanut‐specific IgG4 mAbs (MY‐4‐mAbs) prevents IgE binding to peanut allergens, reduces CD23‐mediated allergen presentation and Th2 responses, and skews immunity towards protective allergen‐specific IgG while limiting allergen‐specific IgE induction. Methods: PBMCs from peanut‐allergic donors were exposed to Ara h 2 with or without MY‐4‐mAbs. Th2 cytokines, Foxp3+ Tregs, and IgE‐facilitated allergen binding (FAB) to B cells were assessed. In vivo, peanut‐sensitized C3H/HeJ mice underwent oral‐AIT with peanut extract with or without MY‐4‐mAbs and were monitored for anaphylaxis during and after oral‐AIT. Additionally, peanut‐specific IgG and IgE levels were measured before and after oral‐AIT. Results: Ex vivo, MY‐4‐mAbs with Ara h 2 suppressed Th2 cytokines, enhanced IL‐10 secretion, and inhibited FAB. MY‐4‐mAbs redirected allergen binding to myeloid antigen‐presenting cells and promoted tolerance‐associated responses. In vivo, the combination maintained peanut‐specific IgG induced during oral‐AIT, prevented increases in IgE, and reduced mast cell activation. Conclusions: Allergen‐specific IgG4 mAbs with controlled allergen exposure may improve the safety and efficacy of peanut AIT while promoting tolerance‐associated immune responses, which might allow disease modification towards allergen tolerance.
- Open Access
- 8 March 2024
- Published by EMBL-EBI
Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- 8 March 2024
- Published by EMBL-EBI
Open AccessDirected evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.
- Open Access
- 3 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex
Antibody drugs exert therapeutic effects via a range of mechanisms, including competitive inhibition, allosteric modulation, and immune effector mechanisms. Facilitated dissociation is an additional mechanism where antibody-mediated “disruption” of stable high-affinity macromolecular complexes can potentially enhance therapeutic efficacy. However, this mechanism is not well understood or utilized therapeutically. Here, we investigate and engineer the weak disruptive activity of an existing therapeutic antibody, omalizumab, which targets IgE antibodies to block the allergic response. We develop a yeast display approach to select for and engineer antibody disruptive efficiency and generate potent omalizumab variants that dissociate receptor-bound IgE. We determine a low resolution cryo-EM structure of a transient disruption intermediate containing the IgE-Fc, its partially dissociated receptor and an antibody inhibitor. Our results provide a conceptual framework for engineering disruptive inhibitors for other targets, insights into the failure in clinical trials of the previous high affinity omalizumab HAE variant and anti-IgE antibodies that safely and rapidly disarm allergic effector cells.
- 3 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Open AccessDirected evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex
Antibody drugs exert therapeutic effects via a range of mechanisms, including competitive inhibition, allosteric modulation, and immune effector mechanisms. Facilitated dissociation is an additional mechanism where antibody-mediated “disruption” of stable high-affinity macromolecular complexes can potentially enhance therapeutic efficacy. However, this mechanism is not well understood or utilized therapeutically. Here, we investigate and engineer the weak disruptive activity of an existing therapeutic antibody, omalizumab, which targets IgE antibodies to block the allergic response. We develop a yeast display approach to select for and engineer antibody disruptive efficiency and generate potent omalizumab variants that dissociate receptor-bound IgE. We determine a low resolution cryo-EM structure of a transient disruption intermediate containing the IgE-Fc, its partially dissociated receptor and an antibody inhibitor. Our results provide a conceptual framework for engineering disruptive inhibitors for other targets, insights into the failure in clinical trials of the previous high affinity omalizumab HAE variant and anti-IgE antibodies that safely and rapidly disarm allergic effector cells.
- 6 July 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (8) , 688-702
Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age
Adipose tissue eosinophils (ATEs) are important in the control of obesity-associated inflammation and metabolic disease. However, the way in which ageing impacts the regulatory role of ATEs remains unknown. Here, we show that ATEs undergo major age-related changes in distribution and function associated with impaired adipose tissue homeostasis and systemic low-grade inflammation in both humans and mice. We find that exposure to a young systemic environment partially restores ATE distribution in aged parabionts and reduces adipose tissue inflammation. Approaches to restore ATE distribution using adoptive transfer of eosinophils from young mice into aged recipients proved sufficient to dampen age-related local and systemic low-grade inflammation. Importantly, restoration of a youthful systemic milieu by means of eosinophil transfers resulted in systemic rejuvenation of the aged host, manifesting in improved physical and immune fitness that was partially mediated by eosinophil-derived IL-4. Together, these findings support a critical function of adipose tissue as a source of pro-ageing factors and uncover a new role of eosinophils in promoting healthy ageing by sustaining adipose tissue homeostasis.
- 6 July 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (8) , 688-702
Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age
Adipose tissue eosinophils (ATEs) are important in the control of obesity-associated inflammation and metabolic disease. However, the way in which ageing impacts the regulatory role of ATEs remains unknown. Here, we show that ATEs undergo major age-related changes in distribution and function associated with impaired adipose tissue homeostasis and systemic low-grade inflammation in both humans and mice. We find that exposure to a young systemic environment partially restores ATE distribution in aged parabionts and reduces adipose tissue inflammation. Approaches to restore ATE distribution using adoptive transfer of eosinophils from young mice into aged recipients proved sufficient to dampen age-related local and systemic low-grade inflammation. Importantly, restoration of a youthful systemic milieu by means of eosinophil transfers resulted in systemic rejuvenation of the aged host, manifesting in improved physical and immune fitness that was partially mediated by eosinophil-derived IL-4. Together, these findings support a critical function of adipose tissue as a source of pro-ageing factors and uncover a new role of eosinophils in promoting healthy ageing by sustaining adipose tissue homeostasis.
- Top Cited PapersOpen Access
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Top Cited PapersOpen AccessThe mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.